Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor–related protein
J. Clin. Invest. Manuel Yepes, et al. 112:1533 doi:10.1172/JCI19212 [
Go to this article.]
Figure 5Changes in vascular permeability following intraventricular injection of tPA, determined by quantitative analysis of Evans blue extravasation from brain extracts. Measurements were performed 1 hour after intraventricular injection of 2.5 μl of either PBS, active tPA (tPA, 0.7 μM), inactive tPA (tPAi, 0.7 μM), active uPA (uPA, 0.9 μM), and active tPA following 1 hour after pretreatment with the NMDA receptor antagonist MK-801 (t+MK) or coinjection of 5 μl of 0.35 μM active tPA in combination with a 25-fold molar excess (9 μM) of the LRP antagonist RAP (t+RAP). The black bars indicate WT C57BL/6J mice and the white bar indicates
Plg–/– C57BL/6J mice. For each condition,
n = 6–8. *
P < 0.01 vs. animals injected with PBS.
